Ed Feener
Founder chez KALVISTA PHARMACEUTICALS, INC.
Fortune : 737 182 $ au 31/03/2024
Profil
Edward P.
Feener is the founder of KalVista Pharmaceuticals Ltd.
(founded in 2011) and KalVista Pharmaceuticals, Inc. (founded in 2004) where he holds the title of Chief Scientific Officer.
He was also an Associate Professor at Harvard Medical School from 1989 to 2016.
Dr. Feener received his doctorate degree from Boston University in 1989.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/02/2024 | 62 157 ( 0,15% ) | 737 182 $ | 31/03/2024 |
Postes actifs de Ed Feener
| Sociétés | Poste | Début |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Founder | 26/03/2004 |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Founder | 01/01/2011 |
Anciens postes connus de Ed Feener
| Sociétés | Poste | Fin |
|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 01/10/2016 |
Formation de Ed Feener
| Boston University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
